A phase I trial of carboplatin and etoposide for elderly (≥75 year-old) patients with small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 5, 2006, Pages 601-606

  Fukuda, Minoru ^a   Soda, Hiroshi ^b   Soejima, Yoshifumi ^c   Fukuda, Masaaki ^d   Kinoshita, Akitoshi ^e   Takatani, Hiroshi ^f   Kasai, Takashi ^b   Nagashima, Seiji ^g   Kawabata, Shigeru ^e   Doi, Seiji ^b   Kohno, Shigeru ^b   Oka, Mikio ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Ureshino Medical Center   (Japan)

^d Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^f Nagasaki Municipal Hospital   (Japan)

^g Sasebo General Hospital   (Japan)

Author keywords

Carboplatin; Chatelut formula; Elderly patients; Etoposide; Small cell lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, SMALL CELL; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; ETOPOSIDE; FEMALE; GASTROINTESTINAL TRACT; HUMANS; INJECTIONS, INTRAVENOUS; LIVER FUNCTION TESTS; LUNG NEOPLASMS; MALE; NAUSEA; NEUTROPENIA; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 33746682452     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0188-7     Document Type: Article

References (34)

1. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics. CA Cancer J Clin 50:7-33
2. Yancik R (1997) Cancer burden in the aged. An epidemiologic and demographic overview. Cancer 80:1273-1283
3. Johnson DH (1997) Small cell lung cancer in the elderly patient. Semin Oncol 4:484-491
4. Murren J, Glatstein E, Pass HI (2001) Small cell lung cancer. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 983-1018
5. Weinmann M, Jeremic B, Bamberg M, Bokemeyer C (2003) Treatment of lung cancer in elderly part II: small cell lung cancer. Lung Cancer 40:1-16
6. Matsui K, Masuda N, Fukuoka M, Yana T, Hirashima T, Komiya T, Kobayashi M, Kawahara M, Atagi S, Ogawara M, Negoro S, Kudoh S, Furuse K (1998) Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. Br J Cancer 77:1961-1965
7. Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N (1999) Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 17:3540-3545
8. Quoix E, Breton JL, Daniel C, Jacoulet P, Debieuvre D, Paillot N, Kessler R, Moreau L, Coetmeur D, Lemarie E, Milleron B (2001) Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol 12:957-962
9. Larive S, Bombaron P, Riou R, Fournel P, Perol M, Lena H, Dussopt C, Philip-Joet F, Touraine F, Lecaer H, Souquet PJ; Groupe Lyon-Saint Etienne d'Oncologie Thoracique (2002) Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer 35:1-7
10. Ardizzoni A, Favaretto A, Boni L, Baldini E, Castinglioni F, Antonelli P, Pari F, Tibaldi C, Altieri AM, Barbera S, Cacciani G, Raimondi M, Tixi L, Stefani M, Monfardini S, Antilli A, Rosso R, Paccagnella A (2005) Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) Study. J Clin Oncol 23:569-575
11. Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR, Ford HT (1987) Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 5:185-189
12. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861
13. Souhami RL, Rudd R, Ruiz de Elvira MC, James L, Gower N, Harper PG, Tobias JS, Partridge MR, Davison AG, Trask C (1994) Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 12:1806-1813
14. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20:4665-4672
15. Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U (2003) Radomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95:1118-1127
16. Loehrer PJ Sr, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH (1995) Cispltin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 13:2594-2599
17. Bishop JF, Raghavan D, Stuart-Harris R, Morstyn G, Aroney R, Kefford R, Yuen K, Lee J, Gianoutsos P, Olver IN (1987) Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 5:1574-1578
18. Evans WK, Eisenhauer E, Hughes P, Maroun JA, Ayoub J, Shepherd FA, Feld R (1988) VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer 58:464-468
19. Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G (1994) Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5:601-607
20. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
21. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing schema for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylato platinum. Cancer Res 45:6502-6506
22. Duffull SB, Robinso BA (1997) Clinical pharmacokinetics and dose optimization of carboplatin. Clin Pharmacokinet 33:161-183
23. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580
24. Fukuda M, Oka M, Soda H, Terashi K, Kawabata S, Nakatomi K, Takatani H, Tsurutani J, Tsukamoto K, Noguchi Y, Fukuda M, Kinoshita A, Kohno S (1999) Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 5:3963-3969
25. Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718-1723
26. WHO (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva
27. Evans WK, Radwi A, Tomiak E, Logan DM, Martins H, Stewart DJ, Goss G, Maroun JA, Dahrouge S (1995) Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 18:149-155
28. Medical Research Council Lung Cancer Working Party (1996) Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomized trial. Lancet 348:563-566
29. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, Lamont A, Harper PG (1997) Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89:577-580
30. Matsui K, Masuda N, Yana T, Takada Y, Kobayashi M, Nitta T, Hirashima T, Fukuoka M (2001) Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med 40:603-606
31. Fukuda M, Oka M, Soda H, Kinoshita A, Fukuda M, Nagashima S, Kuba M, Takatani H, Tsurutani J, Nakamura Y, Kasai T, Inoue Y, Soejima Y, Kohno S; Nagasaki Thoracic Oncology Group (2004) Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemother Pharmacol 54:573-577
32. Kinoshita A, Fukuda M, Fukuda M, Nagashima S, Kuba M, Narasaki F, Takatani H, Kanda T, Kasai T, Tsurutani J, Nakamura Y, Soejima Y, Inoue Y, Soda H, Oka M, Kohno S (2002) A phase II study of irinotecan (CPT-11) and carboplatin (CBDCA) in patients (pts) with small cell lung cancer (SCLC). Proc Am Soc Clin Oncol (Orland) 21:316a (abstr #1260)
33. van Warmerdam LJ, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JH, ten Bokkel Huinink WW, Davies BE, Maes RA, Verweij J, Beijnen JH (1996) Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemother Pharmacol 38:254-260
34. Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG (2004) Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15:291-295